TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23775924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Bladder training
Number of subjects: 202

Group type: COMPARATOR
Intervention: Cognitive treatment (control group)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Pelvic floor training
Number of subjects: 202
Study: 21984428

Group type: EXPERIMENTAL
Intervention: Activated magnetic resonance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no magnetic resonance therapy)
Number of subjects: 0
Study: 20345019

Group type: EXPERIMENTAL
Intervention: HIV seropositive children
Number of subjects: 1024

Group type: COMPARATOR
Intervention: HIV seronegative children
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Chronic ear discharge
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Lymphadenopathy
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Clubbing
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Marasmus
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Hepato-splenomegaly
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Oral candida
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: History of recurrent respiratory infection
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Persistent fever
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Recent outpatient attendance or hospital admission
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Persistent diarrhoea
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Orphaning
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Household contact with TB
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: HIV infected children
Number of subjects: 1024
Study: 17366745

Group type: EXPERIMENTAL
Intervention: Tablet B7 (once daily sustained release tablets of aceclofenac)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marketed product (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tablet B7
Number of subjects: 0
Study: 15117041

Group type: EXPERIMENTAL
Intervention: Potassium chloride (KCl)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Potassium sodium citrate (K Na citrate)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Magnesium glycine (Mg glycine)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Potassium magnesium citrate (K Mg citrate)
Number of subjects: 61
Study: 14564870

Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 20
Study: 9039605

Group type: EXPERIMENTAL
Intervention: Gadolinium chelate-enhanced dynamic MR imaging
Number of subjects: 40
Study: 7951087

Group type: EXPERIMENTAL
Intervention: Na/K/ATPase activity in patients with asthma and COPD
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Na/K/2Cl-cotransport activity in patients with asthma and COPD
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Na/K/ATPase activity
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (15 healthy subjects)
Number of subjects: 57
Study: 2889522

Group type: EXPERIMENTAL
Intervention: OK-432 treatment group
Number of subjects: 382

Group type: COMPARATOR
Intervention: Control treatment group
Number of subjects: 382
Study: 31425459

Group type: EXPERIMENTAL
Intervention: Precooling (cold-water immersion for 15 minutes at 10.1 ± 0.3° C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no precooling)
Number of subjects: 12
Study: 29411232

Group type: EXPERIMENTAL
Intervention: African American patients
Number of subjects: 309

Group type: COMPARATOR
Intervention: Non-African American patients
Number of subjects: 309
Study: 27740639

Group type: EXPERIMENTAL
Intervention: Short dental implants (5.5 or 7 mm)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard dental implants (10 or 12 mm)
Number of subjects: 82
Study: 25287828

Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 416

Group type: COMPARATOR
Intervention: ECX
Number of subjects: 416
Study: 22827974

Group type: EXPERIMENTAL
Intervention: Psychosocial telephone counseling intervention
Number of subjects: 22
Study: 20346518

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg daily for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 2 weeks followed by Escitalopram 10 mg daily for 12 weeks
Number of subjects: 0
Study: 18656769

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg/kg for 10 minutes, followed by 0.5 microg kg(‐1) h(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 40
Study: 16247191

Group type: EXPERIMENTAL
Intervention: Salicylate intolerance evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietetic, diagnostic, and therapeutic options
Number of subjects: 0
Study: 12544629

Group type: EXPERIMENTAL
Intervention: Progressive strength training (3 times weekly, 2 sets of 6-8 repetitions at 70-80% of one repetition maximum)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Weighted squats
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Back extension
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Weighted march exercise
Number of subjects: 140
Study: 10364860

Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% in oxygen with rocuronium 0.3 mg.kg-1
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% in oxygen with rocuronium 0.45 mg.kg-1
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% in oxygen with rocuronium 0.6 mg.kg-1
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Propofol 2-3 mg.kg-1 with rocuronium 0.3 mg.kg-1
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Propofol 2-3 mg.kg-1 with rocuronium 0.45 mg.kg-1
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Propofol 2-3 mg.kg-1 with rocuronium 0.6 mg.kg-1
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% in oxygen without muscle relaxant
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Propofol 2-3 mg.kg-1 without muscle relaxant
Number of subjects: 140
Study: 8659554

Group type: EXPERIMENTAL
Intervention: Comprehensive long-term management program emphasizing inhaled corticosteroids and patient education (beclomethasone with a spacer, inhaled albuterol as needed, crisis prednisone).
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual care from local physicians (Control group).
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Comprehensive long-term management program emphasizing inhaled corticosteroids and patient education.
Number of subjects: 39
Study: 2071733

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) with home practice and application instructions
Number of subjects: 33

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR) without home practice
Number of subjects: 33

Group type: COMPARATOR
Intervention: Symptom monitoring group
Number of subjects: 33
Study: 6362702

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.50 mg and Flunitrazepam 2.0 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brotizolam
Number of subjects: 0
Study: 31075246

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 300

Group type: COMPARATOR
Intervention: Buccal misoprostol
Number of subjects: 300
Study: 30247961

Group type: EXPERIMENTAL
Intervention: Yoga (Dru Yoga, once a week for 12 weeks)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard Care (SC only)
Number of subjects: 83
Study: 27423107

Group type: EXPERIMENTAL
Intervention: 2% tofacitinib ointment twice daily
Number of subjects: 69

Group type: COMPARATOR
Intervention: Vehicle ointment twice daily
Number of subjects: 69
Study: 24919385

Group type: EXPERIMENTAL
Intervention: Meclizine (25 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate (40 mg) combined with Cinnarizine (25 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Promethazine (25 mg) combined with d-Amphetamine (10 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22132997

Group type: COMPARATOR
Intervention: Citrate-based anticoagulation (group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Heparin and low-dose citrate (group H)
Number of subjects: 90
Study: 19913418

Group type: EXPERIMENTAL
Intervention: Pre-operative lymphoscintigraphy
Number of subjects: 117

Group type: COMPARATOR
Intervention: No pre-operative lymphoscintigraphy
Number of subjects: 117
Study: 17397097

Group type: COMPARATOR
Intervention: Naltrexone (50 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine high (1500-1800 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine low (600-900 mg)
Number of subjects: 84
Study: 15911190

Group type: EXPERIMENTAL
Intervention: Evidence-based booklet
Number of subjects: 421

Group type: COMPARATOR
Intervention: Leaflet
Number of subjects: 421

Group type: COMPARATOR
Intervention: Video
Number of subjects: 421
Study: 12576262

Group type: EXPERIMENTAL
Intervention: Phenobarbital and repeated antenatal corticosteroids
Number of subjects: 299
Study: 10384064

Group type: EXPERIMENTAL
Intervention: 2.5 mg of terbutaline
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8680672

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1986440

Group type: EXPERIMENTAL
Intervention: Combination therapy (nifedipine SR + atenolol)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nifedipine SR
Number of subjects: 28

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 28
Study: 6833040

Group type: EXPERIMENTAL
Intervention: One-arm handgrip (HG)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Two-leg extension (LE)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dead-lift (DL)
Number of subjects: 12
Study: 30243187

Group type: EXPERIMENTAL
Intervention: Early anticoagulation treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Location of initial infarction (PCI vs ACI)
Number of subjects: 0
Study: 28577938

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 675

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 675
Study: 25761743

Group type: EXPERIMENTAL
Intervention: Pirarubicin combined with hyaluronic acid
Number of subjects: 127

Group type: COMPARATOR
Intervention: Pirarubicin alone
Number of subjects: 127
Study: 24107284

Group type: EXPERIMENTAL
Intervention: online hemodiafiltration (HDF)
Number of subjects: 28

Group type: COMPARATOR
Intervention: high-flux hemodialysis (HD)
Number of subjects: 28
Study: 20464170

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) three times a week during the initial four weeks of anti-TB treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Anti-TB drugs only (Control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 20
Study: 18788653

Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem tartrate 3.5 mg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Sublingual zolpidem tartrate 1.75 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 17410952

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride (SnF2) dentifrice
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard 0.243% sodium fluoride (NaF) dentifrice
Number of subjects: 14
Study: 12712784

Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 60
Study: 10714624

Group type: EXPERIMENTAL
Intervention: Ultrasonically activated shears (UAS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional method using ligatures
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ultrasonically activated shears (UAS) and Conventional method
Number of subjects: 36
Study: 8823496

Group type: EXPERIMENTAL
Intervention: Oral NK611 at doses of 5, 10, and 20 mg/m2 on day 1, followed by a daily oral dose of 20 mg/m2 from day 4 to day 7 for a total of 85, 90, and 100 mg/m2.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intravenous NK611 (30-min infusion) at doses of 5, 10, and 20 mg/m2 on day 1.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: NK611 (oral and intravenous administration)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: NK611
Number of subjects: 21
Study: 1335640

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (0, 1 and 2 months schedule)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (0, 1 and 6 months schedule)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine
Number of subjects: 104
Study: 6094422

Group type: EXPERIMENTAL
Intervention: 750 mg sultamicillin, 12-hourly (series I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 500 mg sultamicillin, 8-hourly (series II)
Number of subjects: 0
Study: 29489727

Group type: EXPERIMENTAL
Intervention: High-frequency resistance training (HFRT, n = 11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Low-frequency resistance training (LFRT, n = 12)
Number of subjects: 23
Study: 30596721

Group type: EXPERIMENTAL
Intervention: Change in velocity (Δv) of 3 / 6 km/h
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Muscle pre-tension (tense / relaxed)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Seating position (driver / front seat passenger)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Safety belt usage
Number of subjects: 52
Study: 27242220

Group type: EXPERIMENTAL
Intervention: Baseline plasma cytokines (IL-2, IL-4)
Number of subjects: 15
Study: 25155134

Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet system (SSTS) 15 mcg with a 20-minute lockout interval
Number of subjects: 357

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia with morphine sulfate (IV PCA MS) 1 mg with a 6-minute lockout interval
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet system (SSTS)
Number of subjects: 357
Study: 21594234

Group type: EXPERIMENTAL
Intervention: 10% sodium ascorbate (SA) + bleaching with 10% carbamide peroxide (CP) + restoration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) + sodium ascorbate (SA) + restoration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bleaching with 10% carbamide peroxide (CP) + restoration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bleaching with 35% hydrogen peroxide (HP) + restoration
Number of subjects: 0
Study: 20658810

Group type: EXPERIMENTAL
Intervention: MST plus ARC
Number of subjects: 615

Group type: COMPARATOR
Intervention: Control
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: MST only
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: ARC only
Number of subjects: 615
Study: 17457124

Group type: EXPERIMENTAL
Intervention: Sugammadex 8 mg/kg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Sugammadex 4-8 mg/kg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 98
Study: 15088991

Group type: EXPERIMENTAL
Intervention: High sex-hormone-binding globulin levels
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sex-hormone-binding globulin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Patients with vertebral fractures
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sex-hormone-binding globulin, total and free testosterone, and estradiol
Number of subjects: 21
Study: 12532597

Group type: EXPERIMENTAL
Intervention: ximedon-electrophoresis
Number of subjects: 56
Study: 9704236

Group type: EXPERIMENTAL
Intervention: Low-glycemic carbohydrate diet
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High-glycemic carbohydrate diet
Number of subjects: 26
Study: 7807484

Group type: EXPERIMENTAL
Intervention: Single, 1-g dose of cefazolin before clamping of the cord
Number of subjects: 307

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 307
Study: 2534552

Group type: EXPERIMENTAL
Intervention: 20% azelaic acid cream
Number of subjects: 92

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 92

Group type: COMPARATOR
Intervention: 0.05% tretinoin cream
Number of subjects: 92
Study: 1011957

Group type: EXPERIMENTAL
Intervention: Exercise at 49% Vo2max
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exercise at 65% Vo2max
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exercise at 82% Vo2max
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exercise at varying intensities
Number of subjects: 6
Study: 31678425

Group type: EXPERIMENTAL
Intervention: adamgammadex sodium
Number of subjects: 52

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 52
Study: 31013872

Group type: EXPERIMENTAL
Intervention: Non-live bifidobacteria (group H)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Live bifidobacteria (group L)
Number of subjects: 98

Group type: COMPARATOR
Intervention: No intervention (group N)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Comparison of groups H and L to group N
Number of subjects: 98
Study: 28706172

Group type: EXPERIMENTAL
Intervention: Health coaching services (once a week for 8 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Home-visiting nursing services (once a week for 8 weeks)
Number of subjects: 43
Study: 26050541

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 or 0.5 mg)
Number of subjects: 483
Study: 24262392

Group type: EXPERIMENTAL
Intervention: Audiovisual modeling (group I)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (group II)
Number of subjects: 90
Study: 22093843

Group type: EXPERIMENTAL
Intervention: CIM test (current infection marker kit, Genelabs Diagnostics)
Number of subjects: 300
Study: 19508994

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 257
Study: 17877887

Group type: EXPERIMENTAL
Intervention: Short-course, high-dose oral antiviral therapy (specific agents not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of oral antiviral agents (aciclovir, valaciclovir, famciclovir) with topical corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aciclovir, valaciclovir, famciclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylactic therapy for minimally invasive procedures
Number of subjects: 0
Study: 15791515

Group type: EXPERIMENTAL
Intervention: Thermotherapy (1 treatment of >or=1 consecutive application at 50 degrees C for 30 s)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Intralesional sodium stibogluconate (SSG) (5 injections of 2-5 mL every 5-7 days)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Intramuscular sodium stibogluconate (SSG) (20 mg/kg daily for 21 days)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Thermotherapy
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Intralesional SSG
Number of subjects: 401
Study: 11581504

Group type: EXPERIMENTAL
Intervention: Variable practice schedule
Number of subjects: 36

Group type: COMPARATOR
Intervention: Constant practice schedule
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vision of the effector present
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vision of the effector absent
Number of subjects: 36
Study: 9855225

Group type: EXPERIMENTAL
Intervention: Olmed screw
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Tronzo screw
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Ullevaal screw
Number of subjects: 607
Study: 7978470

Group type: EXPERIMENTAL
Intervention: Stress hormone infusion (epinephrine, cortisol, glucagon)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study: 2919759

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 40
Study: 31058797

Group type: COMPARATOR
Intervention: EXERCISE
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EXERCISE+PEH
Number of subjects: 24
Study: 28750232

Group type: EXPERIMENTAL
Intervention: Chair yoga therapy (twice-weekly 20-min sessions for 12 weeks)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Chair yoga therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 56
Study: 25196993

Group type: EXPERIMENTAL
Intervention: Blosozumab 180 mg every 4 weeks (Q4W)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Blosozumab 180 mg every 2 weeks (Q2W)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Blosozumab 270 mg every 2 weeks (Q2W)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Blosozumab (highest dose group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Blosozumab
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 23291970

Group type: EXPERIMENTAL
Intervention: TAP block with ketorolac 30 mg IV and ketorolac plus paracetamol 650 mg orally every 6 h for 24 h (Group 1)
Number of subjects: 74

Group type: COMPARATOR
Intervention: TAP block only (Group 2)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Ketorolac 30 mg IV and ketorolac plus paracetamol 650 mg orally every 6 h for 24 h (Group 3)
Number of subjects: 74
Study: 21273183

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily orally until progression or inacceptable toxicity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent erlotinib and docetaxel (docetaxel 75 mg/m² on day 1 and erlotinib 150 mg orally on days 2‐16, recycled every 3 weeks up to 4 cycles, followed by erlotinib 150 mg daily until disease progression or inacceptable toxicity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent erlotinib and docetaxel
Number of subjects: 0
Study: 19448377

Group type: EXPERIMENTAL
Intervention: 0.5 mL sucrose 24% with pacifier
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0.5 mL sterile water with pacifier
Number of subjects: 36
Study: 16933589

Group type: EXPERIMENTAL
Intervention: Quetiapine added to usual treatment, attempted dosage of at least 400 mg daily.
Number of subjects: 19
Study: 12814405

Group type: EXPERIMENTAL
Intervention: Recent randomised trials in colorectal surgery
Number of subjects: 0